Mithila Samachar

Type 1 Diabetes Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Type 1 Diabetes Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 26
23:30 2022
Type 1 Diabetes  Market  Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Type 1 Diabetes Market:
DelveInsight’s “Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Type 1 Diabetes, historical and forecasted epidemiology as well as the Type 1 Diabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Type 1 Diabetes, historical and forecasted epidemiology as well as the Type 1 Diabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Type 1 Diabetes market report provides current treatment practices, emerging drugs, Type 1 Diabetes market share of the individual therapies, current and forecasted Type 1 Diabetes market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Type 1 Diabetes treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Type 1 Diabetes market.

Some of the key facts of the Type 1 Diabetes Market Report:

  • As per a research by Diabetes UK (2015), in a cohort of diabetes patients, 10% of people with diabetes have Type 1 diabetes and 90% of people with diabetes have Type 2. With the inclusion of children, it was estimated that 15%  of people suffering with diabetes have Type 1 and 85% of people suffering with diabetes have Type 2. It was also estimated that the prevalence of Type 1 diabetes in children and young people under the age of 15 is 187.7 per 100,000.
  • In a study conducted by Rosenbauer et al. (2019), it was reported that in a group of patients aged above 18 years suffering with type 1 diabetes the prevalence of males was 543.5 per 100,000 persons, whereas the prevalence of females reported was 445.0 per 100,000 persons. The prevalence reported for patients between the age group 18-24 years was 425.0, 25-34 years was 509.4, 35-44 years was 683.6, 45-54 years was 488.4, 55-64 years was 467.8 , 65-74 years was 424.2 and for ≥75 years it was 419.3 per 100,000 persons. 

Key Benefits of the Type 1 Diabetes Market report:

  • The report covers the descriptive overview of Type 1 Diabetes , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Type 1 Diabetes  epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Type 1 Diabetes  is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Type 1 Diabetes  market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Type 1 Diabetes  market
  •  

Got queries? Click here to know more about the Type 1 Diabetes Market Landscape

Type 1 Diabetes  Overview

Type 1 Diabetes  (TED) is a complex orbital inflammatory disease, which can be sight threatening, debilitating and disfiguring. TED is also known as Graves’ ophthalmopathy, named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman presenting with goiter, rapid heartbeat and exophthalmos.TED affects eye muscles, eyelids, tear glands and fatty tissues behind the eye become inflamed. This can cause the eyes and eyelids to become red, swollen and uncomfortable and the eyes can be pushed forward (‘staring’ or ‘bulging’ eyes).

 

Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking, because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations.

The key players are strengthening their market position through strategic mergers, agreements, and acquisitions which is expected to propel growth of the thyroid eye disease treatment market over the forecasted period (2019-2032). For instance, in May 2017, Horizon Therapeutics acquired the River Vision Development Corp. and its pipeline drug teprotumumab, a human monoclonal antibody for the treatment of thyroid eye disease. This acquisition is expected to cater unmet needs for the treatment of thyroid eye disease.

Type 1 Diabetes Epidemiological Insight

  • According to the National Diabetes Statistics Report (2020), 34.2 million people in the United States will have diabetes in 2018, accounting for 10.5% of the total population. 
  • In 2018, 210,000 children and adolescents under the age of 20 in the United States were diagnosed with diabetes, of which 187,000 people had type 1 diabetes diagnosis. By the coming year, these cases are expected to increase (National Diabetes Statistics Report, 2020).
  • Type 1 diabetes may affect anybody at any age, although it impacts children and adolescents the most commonly. Over one million children and adolescents under the age of 20 have type 1 diabetes, according to the International Diabetes Federation (IDF).

Type 1 Diabetes  Market  Epidemiological Segmentation 

  •  Total Prevalent Cases of Type 1 diabetes 
  •  Total gender-specific prevalent diagnosed  cases of Type 1 Diabetes i
  • Treated cases of Type 1 Diabetes  
  • Total age-specific prevalence of diagnosed cases of Type 1 Diabetes

Type 1 Diabetes Market Outlook 

The Type 1 Diabetes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Type 1 Diabetes market trends by analyzing the impact of current Type 1 Diabetes therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Type 1 Diabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Type 1 Diabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Type 1 Diabetes market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @Type 1 Diabetes Market Landscape

Type 1 Diabetes Key Companies  

  •  Prevention Bio
  •  Toleration
  •  Dompe Pharmaceutical
  • And others

Type 1 Diabetes  Therapies 

  •  Teplizumab
  •  TOL-3021
  •  Ladarixin 
  •  AG019
  • And others

Table of Contents

  •  Key Insights 
  • Report Introduction 
  •  Executive Summary of Type 1 Diabetes  
  • Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  • Type 1 Diabetes    Emerging Therapies
  •  Type 1 Diabetes   Market Outlook
  •  Market Access and Reimbursement of Therapies
  • Appendix
  •  Type 1 Diabetes   Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/